Engineering immune therapy against hepatitis B virus

Hepatology Research

Volumn 37, Issue SUPPL. 3, 2007, Pages

  Akbar, Fazle ^a   Yoshida, Osamu ^a   Abe, Masanori ^a   Hiasa, Yoichi ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Combination therapy; Dendritic cells; Hepatitis B surface antigen; Hepatitis B virus; Immune therapy; Vaccine therapy

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CY 1899; DENDRITIC CELL VACCINE; DNA VACCINE; ENTECAVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERLEUKIN 12; INTERLEUKIN 2; LAMIVUDINE; PEGINTERFERON; THYMOSIN ALPHA1; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CLINICAL TRIAL; CONFERENCE PAPER; CONVALESCENCE; CYTOLOGY; DISEASE COURSE; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INCIDENCE; INNATE IMMUNITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SELECTION; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS CARRIER; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS TRANSMISSION;

EID: 35348884801     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00251.x     Document Type: Conference Paper

References (22)

1. Wong DK, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A Metaanalysis. Ann Intern Med 1993; 119: 312-23.
2. Hadziyannis SJ. New developments in the treatment of chronic hepatitis B. Expert Opin Biol Ther 2006; 6: 913-21.
3. Rehermann B. Intrahepatic T cells in hepatitis B: Viral control versus liver cell injury. J Exp Med 2000; 191: 1263-8.
4. Bertoletti A, Gehring AJ. The immune response during hepatitis B virus infection. Gen Virol 2006; 87: 1439-49.
5. Spengers D, Janssen HLA. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005; 19: 447-7.
6. Bertoletti A, Maini M, Williams R. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005; 19: 17-26.
7. Heathcote J, McHutchison J, Lee S et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30: 531-6.
8. Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006; 24: 4482-9.
9. Akbar SM, Furukawa S, Horiike N et al. Vaccine therapy for hepatitis B virus carrier. Curr Drug Targets Infect Disord 2004; 4: 93-101.
10. Horiike N, Fazle Akbar SM, Michitaka K et al. In vivo immunization by vaccine therapy following virus suppression by lamivudine: A novel approach for treating patients with chronic hepatitis B. J Clin Virol 2005; 32: 156-61.
11. Araki K, Miyazaki J, Hino O et al. Expression and replication of hepatitis B virus genome in transgenic mice. Proc Natl Acad Sci USA 1989; 86: 207-11.
12. Akbar SMF, Abe M, Masumoto T et al. Mechanism of action of vaccine therapy in murine hepatitis B virus- carriers: Vaccine-induced activation of antigen presenting dendritic cells. J Hepatol 1999; 30: 755-64.
13. Akbar SMF, Onji M, Inaba K et al. Low responsiveness of hepatitis B virus transgenic mice in antibody response to T-cell-dependent antigen: defect in antigen presenting activity of dendritic cells. Immunology 1993; 78: 468-73.
14. Akbar SMF, Horiike N, Onji M. Prognostic importance of antigen presenting dendritic cells during vaccine therapy in murine hepatitis B virus carriers. Immunology 1999; 96: 98-108.
15. Arima S, Akbar SMF, Michitaka K et al. Impaired function of antigen-presenting dendritic cells in patients with chronic hepatitis B: localization of HBV DNA and HBV RNA in blood DC by in situ hybridization. Int J Mol Med 2003; 11: 169-74.
16. Beckebaum S, Cicinnati VR, Dworacki G et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002; 104: 138-50.
17. Onji M. Dendritic Cells in Clinics. Tokyo: Springer, 2004.
18. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52.
19. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
20. Akbar SMF, Furukawa S, Hasebe A et al. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrier. Int J Mol Med 2004; 14: 295-9.
21. Furukawa S, Akbar SMF, Hasebe A et al. Production of hepatitis B surface antigen-pulsed dendritic cells from immunosuppressed murine hepatitis B virus carrier: Evaluation of immunogenicity of antigen-pulsed dendritic cells in vivo. Immunobiology 2004; 209: 551-7.
22. Akbar SMF, Furukawa S, Onji M et al. Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers. Hepatol Res 2004; 29: 136-41.